Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of AZD0837 in patients
with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for
up to 3 months.